Regulation, reimbursement and HTA hold up EU access to cancer drugs, says report
This article was originally published in SRA
Executive Summary
Access to cancer drugs by patients in the European Union can be significantly restricted by regulatory obstacles, pricing and reimbursement hurdles and health technology assessment procedures, a new industry-sponsored report has indicated1.